Cassava Sciences, Inc.
SAVA
$2.05
-$0.07-3.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -10.30M | -7.73M | -33.76M | -27.83M | -28.41M |
| Gross Profit | 10.30M | 7.73M | 33.76M | 27.83M | 28.41M |
| SG&A Expenses | 67.23M | 66.01M | 70.91M | 61.14M | 18.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 134.30M | 135.65M | 138.75M | 134.90M | 102.28M |
| Operating Income | -134.30M | -135.65M | -138.75M | -134.90M | -102.28M |
| Income Before Tax | -72.79M | -24.34M | -17.66M | -15.37M | -47.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.79 | -24.34 | -17.66 | -15.37 | -47.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.79M | -24.34M | -17.66M | -15.37M | -47.90M |
| EBIT | -134.30M | -135.65M | -138.75M | -134.90M | -102.28M |
| EBITDA | -133.26M | -134.51M | -137.52M | -133.54M | -100.83M |
| EPS Basic | -1.51 | -0.44 | -0.36 | -0.39 | -1.16 |
| Normalized Basic EPS | -0.79 | -0.20 | -0.28 | -0.29 | -0.76 |
| EPS Diluted | -1.51 | -1.45 | -1.38 | -1.41 | -2.17 |
| Normalized Diluted EPS | -0.79 | -0.21 | -0.29 | -0.29 | -0.77 |
| Average Basic Shares Outstanding | 190.54M | 185.28M | 179.37M | 173.39M | 168.98M |
| Average Diluted Shares Outstanding | 190.54M | 186.38M | 180.47M | 174.49M | 170.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |